Dual institution experience of extranodal marginal zone lymphoma reveals excellent long-term outcomes.

@article{Starr2016DualIE,
  title={Dual institution experience of extranodal marginal zone lymphoma reveals excellent long-term outcomes.},
  author={A. G. Starr and Paolo Fabrizio Caimi and Pingfu Fu and Mira Romany Massoud and Howard J. Meyerson and E D Hsi and David B. Mansur and Sheen Cherian and Arun Singh and Brenda Wimpfheimer Cooper and Marcos de Lima and Hillard M Lazarus and Stanton L. Gerson and Deepa Jagadeesh and Mitchell R. Smith and Robert D. Bradley Paul R. Krausman Nancy E. McIntyre Acce Dean and Brad L. Pohlman and Brian T. Hill and Basem Magdy William},
  journal={British journal of haematology},
  year={2016},
  volume={173 3},
  pages={404-12}
}
Extranodal marginal zone lymphoma (EMZL) is a B-cell lymphoma arising from mucosa-associated lymphoid tissue (MALT). The disease characteristics, clinical course and treatment vary considerably based on site of involvement. Because long-term outcome data for EMZL are limited, we sought to describe the clinical details of a large number of patients with EMZL evaluated at the Case Comprehensive Cancer Center over a 12-year period to identify prognostic markers including the impact of site of… CONTINUE READING